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Abstract
Schizophrenia is a highly heritable neuropsychiatric disorder of complex genetic etiology. 
Previous genome-wide surveys have revealed a greater burden of large, rare CNVs in 
schizophrenia cases and identified multiple rare recurrent CNVs that increase risk of 
schizophrenia although with incomplete penetrance and pleiotropic effects. Identification of 
additional recurrent CNVs and biological pathways enriched for schizophrenia CNVs requires 
greater sample sizes. We conducted a genome-wide survey for CNVs associated with 
schizophrenia using a Swedish national sample (4,719 cases and 5,917 controls). High-confidence 
CNV calls were generated using genotyping array intensity data and their effect on risk of 
schizophrenia was measured. Our data confirm increased burden of large, rare CNVs in 
schizophrenia cases as well as significant associations for recurrent 16p11.2 duplications, 22q11.2 
deletions and 3q29 deletions. We report a novel association for 17q12 duplications (odds 
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ratio=4.16, P=0.018), previously associated with autism and mental retardation but not 
schizophrenia. Intriguingly, gene set association analyses implicate biological pathways 
previously associated with schizophrenia through common variation and exome sequencing 
(calcium channel signaling and binding partners of the fragile X mental retardation protein). We 
found significantly increased burden of the largest CNVs (>500Kb) in genes present in the post-
synaptic density, in genomic regions implicated via schizophrenia genome-wide association 
studies, and in gene products localized to mitochondria and cytoplasm. Our findings suggest that 
multiple lines of genomic inquiry – genome-wide screens for CNVs, common variation, and 
exonic variation – are converging on similar sets of pathways and/or genes.
Keywords
schizophrenia; genetics; genomics; copy number variation; structural variation
Introduction
Schizophrenia is an often devastating psychiatric disorder with substantial morbidity, 
mortality, and personal and societal costs.1–3 An important genetic component is indicated 
by a sibling recurrence risk of 8.6, high heritability estimates (0.64 in a national family 
study, 0.81 in a meta-analysis of twin studies, and 0.32 estimated directly from common 
SNPs), and prior genomic findings.4–7
Recent studies into the genetic architecture of this disease have identified both common and 
rare variation.7–13 GWAS have implicated 22 genome-wide significant loci plus biological 
pathways including genes regulated by miR-137, neuronal calcium channel signaling, and 
binding partners of fragile X mental retardation protein (FMRP). Exome sequencing of 
2,536 schizophrenia cases and 2,543 controls implicated gene sets enriched for rare exonic 
variations, including genes involved in calcium channel signaling, FMRP interactors, and 
the neuronal activity-regulated cytoskeleton-associated (ARC) complex of the postsynaptic 
density (PSD).14 Genomic evaluation of copy number variation (CNV) has established a 
role for large rare CNVs (>100 kb, <1%) in risk for schizophrenia. Multiple studies have 
reported a greater burden of rare CNVs in schizophrenia cases versus controls.15–17 Eight 
rare CNVs of strong effect (odds ratio 4–20) increase risk for schizophrenia (e.g., 22q11del 
and 16p11dup), and are often recurrent mutations in genomic hotspots with incomplete 
penetrance and pleiotropy.10,11,13 Enrichment analyses of genes intersected by rare CNVs 
implicated functional categories related to synaptic activity and neurodevelopment, and 
components of the PSD (particularly the N-methyl-D-aspartate receptor, NMDAR, and ARC 
complexes).12,15,18
The cumulative results from genomic studies of common and rare variation strongly suggest 
that schizophrenia is notably polygenic (i.e., many genes of differing effect sizes confer the 
risk for schizophrenia). Besides the eight CNVs of strongest effects,13 it remains unclear 
whether additional CNVs contribute to the risk for schizophrenia. Larger samples are 
required to yield new insights and identify novel loci of lower frequencies or modest effects.
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Of particular interest, several gene sets (e.g., calcium channel signaling and FMRP 
interactors) have convergent genomic results from GWAS and exome sequencing. This 
convergence from different methodologies minimizes risk of bias and suggests that different 
types of alleles can perturb the same biological pathways that contribute to the etiology of 
schizophrenia. However, it remains unclear whether CNVs similarly play a role in these 
pathways of high risk. Previous enrichment analyses of genes intersected by rare CNVs did 
not explicitly examine the relationship between rare CNVs and common SNPs.
The purpose of this study was to identify CNV alleles, genes, or gene sets that confer risk 
for schizophrenia in a well-powered sample and to examine the overlap and relative impact 
of common SNPs and rare CNVs. We conducted a genome-wide CNV survey in a Swedish 
sample (4,719 cases with schizophrenia and 5,917 controls)7. This sample is well suited for 
this study given its national sampling frame and relative homogeneity. While the primary 
data source were genome-wide SNP arrays, all samples were also genotyped with Illumina 
exome arrays enabling CNV validation with an independent technology.19
Materials and Methods
Additional information is in the Supplemental Methods. To advance knowledge of 
schizophrenia, CNV data on subsamples were included in prior reports.20,21 We present here 
the primary analyses for this project, and note that CNV data for 57% of the sample have 
never been reported before.
Subjects
Subject ascertainment, diagnosis, and validation are described elsewhere7 and summarized 
in the Supplemental Methods. Briefly, all procedures were approved by ethical committees 
in Sweden and the US, and all subjects provided written informed consent. Cases with 
schizophrenia were identified using the Swedish Hospital Discharge Register 22,23 which 
captures all public and private inpatient hospitalizations.24–27 Case inclusion criteria: ≥2 
hospitalizations with a discharge diagnosis of schizophrenia, both parents born in 
Scandinavia, and age≥ 18 years. Case exclusion criteria: hospital register diagnosis of any 
medical or psychiatric disorder mitigating a confident diagnosis of schizophrenia. The 
validity of this case definition of schizophrenia is strongly supported as detailed in the 
Supplementary Note of reference 7. Controls were selected at random from Swedish 
population registers, with the goal of obtaining an appropriate control group and avoiding 
“super-normal” controls that can cause substantial bias in psychiatric research. 28,29 Control 
inclusion criteria: never hospitalized for schizophrenia or bipolar disorder, both parents born 
in Scandinavia, and age ≥18 years. Participation rates were lower for cases than for controls 
(53.3% versus 58.3%) but similar to participation rates in epidemiology (41% for cross-
sectional and 56% for case-control studies),30,31 and a large Norwegian longitudinal study 
(42%).
Genotyping and quality control
DNA was extracted from peripheral venous blood for all subjects. Genotyping was done in 
six batches (Sw1–6) at the Broad Institute using Affymetrix 5.0 (3.9%, Sw1), Affymetrix 
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6.0 (38.6%, Sw2–4), and Illumina OmniExpress (57.4%, Sw5–6). Genotypes were called 
using Birdsuite (Affymetrix) or BeadStudio (Illumina). Quality control filters excluded 
SNPs for missingness ≥ 0.05 or minor allele frequency < 0.01 and subjects for missingness ≥ 
0.02, autosomal heterozygosity deviation, and one of any pair of subjects with high 
relatedness (π̂ > 0.2). A total of 11,244 subjects (5,001 cases with schizophrenia and 6,243 
controls) remained and were used for subsequent CNV calling and quality control. All 
genomic locations are given in NCBI build 37/UCSC hg19 coordinates.
CNV calling and quality control
We used Birdseye to detect CNVs.32 Birdseye applies a hidden Markov model to 
normalized probe intensities using model priors tuned to each GWAS array. Basic quality 
control included removal of low-confidence CNVs with confidence scores < 10, spanning < 
10 probes, or < 10 kb in length32 followed by removal of CNVs with > 50% reciprocal 
overlap with large genomic gaps (e.g., centromeres) or regions subject to rearrangement in 
white blood cells. We annealed adjoining CNVs that appeared to be artificially split by 
Birdseye by recursively joining CNVs if the called region is ≥ 80% of the entire region to be 
joined. The largest CNVs (≥ 5 Mb) and chrX CNVs were visually inspected and those of 
low confidence were removed. We excluded subjects whose genotyping arrays had 
excessive noise (probe intensity variance or genomic “waviness” exceeding platform 
specific thresholds, Table S3, Figure S1) or excessive CNV calls scattered across many 
chromosomes (≥ 40 segments or total length ≥ 6 Mb). These procedures resulted in a final 
sample size of 10,636 subjects (4,719 cases and 5,917 controls, Table S4).
Because Birdseye was optimized to identify rare CNVs,32 we imposed a 0.01 frequency 
threshold by removing CNVs with > 50% of its length spanning a region with > 107 CNVs. 
Our main analyses were conducted using CNVs ≥ 100 kb and spanning ≥ 15 probes, which 
gave an estimated false positive rate of 3.3% based on NanoString validation of 212 CNVs 
detected from Affymetrix 6.0 SNP arrays (unpublished data).
CNV validation
The same DNA samples from all cases and controls were genotyped on Illumina exome 
arrays. We develop CNV calling procedures for these data (essentially, an exon-focused set 
of 250K probes), and have shown that the exome array has high sensitivity and specificity to 
identify CNVs ≥ 400 kb.19 Therefore, we used these additional data for large-scale 
validation. A CNV (≥400 kb) is considered validated if it is overlapped by an exome array 
CNV in the same sample by 50% of its length. Table S5 displays the validation results 
stratified by array type and for deletions and duplications separately and combined. The 
validation rates were 89%, 83%, and 92% for Affymetrix 5.0, Affymetrix 6.0, and Illumina 
Omni Express arrays. For all nominally associated CNVs that had sufficient probe coverage 
from the exome array, we manually inspected CNV calls and probe intensity plots in the 
same samples.
Statistical analysis
All analyses were conducted using PLINK33 and R.34 As confounders can create spurious 
associations, we tested a series of metrics (Table S7) for their impact on genome-wide CNV 
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burden using multiple logistic regression with genotyping batch, subject ancestry, age, and 
sex included as covariates. As anticipated, genotyping batch (Sw1–6) could potentially 
influence association testing and was controlled for in all analyses. For each association test, 
100,000 permutations were performed to evaluate statistical significance with the 
permutation procedure swapping case-control status within genotyping batches to control for 
batch effect.20 As shown in Table S4, each genotyping batch used one specific type of 
arrays. Thus, controlling for genotyping batch effect simultaneously controlled for the 
difference in genotyping method as permutation swapped case-control status within a 
specific array type.
Genome-wide burden analysis—We conducted burden analyses across a range of 
CNV frequencies, sizes, and types. The burden of rare CNVs was measured as the number 
of CNVs, the genomic length impacted by CNVs, and the number of genes impacted by 
CNVs (“gene count”) using one-sided statistical tests (assuming increased CNV burden in 
cases). Odds ratios measure the increase in the likelihood of having disease per unit increase 
in CNV burden, and were computed in R using logistic regression with batch as a covariate.
Known loci—Large CNVs with previously reported associations with schizophrenia, other 
psychiatric disorders, or developmental delay (Table 2)10,11,13,35,36 were examined using 
regional association testing in PLINK for deletions and duplications separately. For single 
genes, (i.e. NRXN1, VIPR2), we considered all >100kb CNV events that disrupted the gene 
(≥1bp overlap). For all other regions, we considered all >100kb CNV events that had >50% 
reciprocal overlap with a region (PLINK --cnv-union-overlap 0.5). Odds ratios and 
confidence intervals were computed in R. When zero events occurred, odds ratios were 
estimated by applying the standard continuity correction (i.e., adding 0.5 to each cell of the 
2x2 table). 37
Single-site and gene-based association—We excluded known CNV loci in an 
attempt to identify novel deletions or duplications. The single-site analysis compared the 
number of CNV events between cases and controls per marker, where PLINK defines 
markers as to the start and stop sites of all CNV segments. For gene-based association, we 
used Ensembl gene models (20,007 protein coding genes)38 and, for each gene, we 
determined the counts of CNVs disrupting the gene (≥1bp overlap) in cases versus controls. 
To select loci for validation and replication, we extracted nominally associated loci (P < 
0.01) and excluded spurious CNVs by manually inspecting probe intensities and overlap 
with segmental duplications.
Statistical power—Power analyses to detect single CNV loci were conducted using the 
R/gap package (see URLs). Assuming a dominant model, lifetime risk of SCZ of 0.7%,39 
and α =0.05, we computed the minimal detectable genotypic risk ratio to achieve 20%, 25%, 
80%, 90%, or 95% power over a range of frequency of risk alleles in the population (Figure 
1). An additive model produced nearly identical results.
Gene set analyses—We evaluated the collective effects of rare CNVs in predefined sets 
of genes using the “--cnv-enrichment-test” in PLINK relative to all genic CNVs (i.e. CNVs 
overlapping any gene by ≥1bp). This method explicitly compares the rate of CNVs 
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impacting a specific gene set in cases versus controls while controlling for sources of bias.40 
Restricting to only genic CNVs ensures specificity of the enrichment to the set of interests.40 
Specifically, PLINK fits a logistic regression model: 
, where Pi is the probability that individual i is 
affected, ci is the number of genic-CNVs that an individual i has, si is the mean size of those 
events measured in kb, gi is the count of genes within a given gene set affected by genic-
CNVs, and other terms are logistic regression coefficients. The “--cnv-enrichment-test” tests 
if γ, the coefficient associated with gene counts, is significantly different from 0 and 
evaluates its statistical significance via 100,000 permutations swapping case-control status 
within genotyping batches to control for batch effect.20 To estimate odds ratios for the 
increased risk of SCZ per affected gene, we fit the above logistic regression model with 
genotyping batch included as an additional covariate and computed eγ where γ is the 
estimated coefficient associated with gene counts after correcting for background difference 
in rate and size of genic-CNVs and genotyping batch effect.
To discover novel gene sets associated with schizophrenia, we used established pathways 
(KEGG, GO)41–45 and TargetScan (v6.2, predicted 3′ UTR targets of micro-RNAs).46 To 
assess gene sets previously implicated in schizophrenia and other psychiatric disorders, we 
analyzed neuronal calcium signaling genes, genes making RNAs that bind to FMRP (fragile 
X mental retardation protein, the product of FMR1),7,14,47 genes spanned by a de novo CNV 
in Kirov et al,12 genes making proteins found in the neuronal postsynaptic density,12 expert-
curated lists of synaptic genes,48 the “genes2cognition” database,49 genes implicated in 
autism50 or mental retardation,45,51–53 genes whose knock-out in mouse yields a 
neurological or behavioral phenotype,54,55 and human nuclear-encoded mitochondrial genes 
in MitoCarta.56 All gene sets were established a priori and independently of this work. 
Kirov et al12 reported that eight de novo CNVs overlapped four known SCZ-associated 
CNVs (3q29, 15q11.2, 15q13.3 and 16p11.2).
To correct for multiple comparisons in the discovery analysis (i.e. KEGG, GO, TargetScan), 
we used the false discovery rate (FDR) control as implemented in R/qvalue. 57 Given the 
discovery nature of the analysis, FDR is less conservative than Bonferroni approach and has 
greater power to find truly significant results while effectively reducing false positives. To 
correct for multiple comparisons in the analysis of gene sets previously implicated in SCZ, 
we applied the Holm-Bonferroni (HB) 58 method and acknowledge the conservativeness of 
this approach. The HB adjusted P-values (adj_P) were computed in R considering all 126 
association tests performed to establish statistical significance. For each significant 
enrichment identified, we examined specific genes affected by CNVs driving the enrichment 
and their potential overlap with known CNVs/genes associated with schizophrenia and other 
psychiatric disorders.
Rare CNVs and significant GWAS loci—We evaluated whether CNVs in 
schizophrenia cases were enriched for smaller GWAS P-values. The GWAS P-values were 
obtained from a meta-analysis of the Swedish samples (5,001 cases with SCZ and 6,243 
controls) and independent Psychiatric Genomic Consortium (PGC) samples (8,832 cases 
with SCZ and 12,067 controls). 7 There were 2,691 genes with P < 10−3. We applied a 
Szatkiewicz et al. Page 6






















logistic regression model40 for the likelihood of schizophrenia as a function of having a 
CNV overlapping any of these genes while accounting for background differences in the rate 
and size of genic CNVs. The extended MHC region (chr6:25–34 mb) was excluded and the 
“--cnv-enrichment-test” in PLINK relative to all genic CNVs was used with permutation to 
control for batch effects.
Rare CNV and risk profile score burden—We evaluated the relative impact of rare 
CNV burden and common variant allelic burden (i.e., risk profile scores, RPS)7,20,59 on risk 
of schizophrenia. RPS were used the 2011 PGC GWAS mega-analysis9 as the discovery set 
and then computed in the independent Swedish subjects using the -score function in PLINK. 
We selected high-quality, relatively independent PGC SNPs with unambiguous directions of 
effect using a threshold of PT < 0.01 (described in reference 7). For rare CNVs, we use the 
data from the Swedish sample and focused on the number of CNV events as burden metrics. 
We first evaluated the burden of known SCZ-associated CNVs that were replicated at the 
nominal level in the Swedish sample (1q21.1del, 3q29del, 15q13.3del, 22q11.2del, 
16p11.2dup). We evaluated the burden of all >100kb CNVs stratified by type, size, and 
frequency categories. We fit an additive logistic regression model of disease status on RPS 
and rare CNV burden as predictors and genotyping batch as covariate. An additive model is 
justified because the Spearman correlations between CNV burden and RPS were all near 
zero (P > 0.05) and the interaction term, when included in the logistic regression model, was 
not significant. To estimate the proportion of variance in case-control status accounted for 
by RPS and CNV burden, we computed the difference in the Nagelkerke pseudo R2 score 
contrasting a full model with a reduced model in a series of logistic regression models: (1) 
logit(Pr(case)) ~ RPS burden + CNV burden + genotyping batch. (2) logit(Pr(case)) ~ RPS 
burden + genotyping batch. (3) logit(Pr(case)) ~ genotyping batch. For RPS, the pseudo R2 
contrast model (2) with (3). For CNV burden, the pseudo R2 contrast models (1) with (2). 
CNV burden could also be obtained by contrasting a logistic regression model containing 
CNV burden plus batch covariate with (3), which gave the same results because of the 
independence of RPS and CNV burden.
Exploratory analyses
Bloom syndrome (OMIM #210900) is characterized by excessive homologous 
recombination in affected individuals, and is caused by mutations in BLM. Using the 
subsample with exome sequencing genotypes,14 we compared CNV burden between 
individuals with and without deleterious mutations in BLM by fitting a linear model that had 
CNV burden as dependent variable, BLM mutation status as a predictor and genotyping 
batch as covariate.
Replication
We obtained replication association results from 6,882 schizophrenia cases and 11,255 
controls. Cases were from the United Kingdom CLOZUK and CardiffCOGS samples.8 
Cases were genotyped at the Broad Institute using Illumina OmniExpress or OmniCombo 
arrays. Controls were from four external studies of non-psychiatric disorders. Details of the 
replication samples and CNV calling and quality control are documented in Supplementary 
Methods. Replication was attempted for all novel association regions with P < 0.01 in the 
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Swedish case-control comparisons. For each region, we applied matching procedures to 
count the number of CNV events in the UK samples. Specifically, for single genes, we 
computed the counts of CNV events disrupting the gene (≥1bp overlap). For all other region, 
we computed the counts of CNV events that overlapped the region by >50% of its length. 
Statistical testing for replication was using Fisher’s exact test and the stratified Cochran-
Mantel-Hänszel exact test to account for the case-control ratio difference between the 
Swedish and the UK samples.
Results
Large chromosomal anomalies can be identified using genotyping arrays. 60 We identified 
four schizophrenia cases and three controls as genomic outliers (defined as > 40 CNVs or > 
6 Mb, thresholds determined empirically as > 3 SD above the sample means). Six of seven 
abnormalities were confirmed using a second technology (Table S6 and Figure S2). One 
case and one control had trisomy of chr8 or chr3 (Figure S2a–b), both confirmed using 
qPCR.60 Three individuals had deletion (one case) or duplication events (two controls) at 
15q11.2 (20.5Mb – 22.5 Mb, Figure S2f), which overlapped a CNV associated with mental 
retardation. One case (Figure S2g) had multiple deletions that appeared to be consistent with 
mosaicism. Due to their large size, all seven individuals with genomic outliers were 
excluded from all subsequent analyses.
Extensive quality control procedures (Figure 2) were used to establish a stringent CNV 
dataset in 4,719 schizophrenia cases and 5,917 controls (Table 1, Table S8). There was no 
case-control or chip bias in the proportions of CNV deletions or median CNV size. 
However, chip effects were observed in the mean numbers of CNVs per subject. We 
observed greater mean numbers of CNVs in cases than in controls with ratios that varied by 
chip type, most notably in the 3.9% samples that were genotyped on the older platform 
Affymetrix 5.0. Therefore, we controlled for chip effect in all analyses as detailed in 
Methods so that our findings are robust against this confounder.
Genome-wide CNV burden
We assessed the role of rare CNVs >100kb. CNVs were stratified by type, frequency, and 
size. We computed odds ratios (ORs) using logistic regression with genotyping batch as a 
covariate. Complete results are in Tables S9–10 and summarized in Figure 3. We confirmed 
the literature finding that schizophrenia cases had a significantly greater genome-wide 
burden of CNVs than controls: ORs of 1.07 per CNV (95% CI 1.03–1.11, Pemp = 3x10−4), 
1.02 (95% CI 1.01–1.03, Pemp = 1x10−5) per gene affected by CNVs, and 1.02 (95% CI 
1.01–1.03, Pemp = 3x10−5) per 100Kb affected by CNVs. Deletions were enriched in cases 
to a greater extent than duplications. The rarest CNVs (single occurrence) and the largest 
CNVs (> 500 kb) were enriched in cases to a greater extent than other frequency or size 
categories. As expected, the rarest deletions (OR 1.34 per single-occurrence deletion, 95% 
CI 1.12–1.6, Pemp = 6x10−4) and the largest deletions (OR 1.4 per >500 kb deletion, 95% CI 
1.16–1.7, Pemp = 4x10−4) showed the strongest effects albeit with broad CIs. Next, we 
examined the distribution of event size in the rarest deletions (Table S11); and for all size 
categories (100–200kb, 200–500kb, >500kb), we observed greater OR estimates using 
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single-occurrence deletions compared to those obtained from corresponding categories using 
all deletions. Similarly, we examined the distribution of allele frequency in the largest 
deletions (Table S12); and for single- and 2–6 occurrence categories, we observed greater 
OR estimates using >500kb deletions compared to those obtained from corresponding 
categories using all deletions. The highest OR was obtained in >500kb single-occurrence 
deletions. These results (Tables S11–12), although based on a smaller sample size, imply 
that size and rarity could be independent predictors of case-controls status in the Swedish 
sample.
Finally, the largest size category (>500 kb) included CNVs in known schizophrenia-
associated regions that were enriched in cases (Table 2). After excluding 42 CNVs in these 
regions, the OR was 1.17 per >500 kb CNV (95% CI 1.01–1.31, Pemp =0.033), slightly 
smaller than in the full data (OR=1.26), and was mostly due to single-occurrence deletions 
(OR = 1.77, 95% CI 1.11–2.82, Pemp =0.011).
CNV loci
We examined regions known to increase risk for schizophrenia and other psychiatric 
disorders.10,11,13 Complete results are shown in Table 2 and are briefly summarized below. 
We previously verified these CNVs using exome genotyping arrays. 19 We confirmed 
literature findings of associations between risk for schizophrenia and 22q11.2 deletions 
(OR=15.06, 95% CI: 1.48-Inf, Pemp =0.0037), 16p11.2 duplications (OR=6.28, 95% CI: 
1.34–59, Pemp =0.0031), and 3q29 deletions (OR=15.06, 95% CI: 1.48-Inf, Pemp =0.009). 
Weaker evidence was observed for 15q13.3 deletions (OR=4.39, 95% CI: 0.84–43.34, Pemp 
=0.05) and 1q21.1 deletions (OR=6.27, 95% CI: 0.7–296.4, Pemp =0.048). We observed 
more deletions disrupting NRXN1 exons in SCZ cases (2 deletions in cases disrupting one 
exon of NRXN1 but 0 exonic deletion in controls (Figure S5)). We observed more 
duplications at 22q11.2 in controls (0 cases and 5 controls), of which three spanned the full 
length of the known 22q11.2 deletion locus and two spanned ~30%. The full report of 
22q11.2 duplications in a careful CNV analysis of 47,005 individuals (21,138 SCZ cases 
and 25,867 controls) has recently been published,61 where the discovery sample included 
controls across studies of both psychiatric and non-psychiatric phenotypes and the 
replication samples were obtained from multiple sources including our Swedish sample. 
Rees et al 61 reported 22q11.2 duplications as significantly less common in SCZ cases than 
in the general population (0.014% vs 0.0085%, OR=0.17, P=0.00086) and suggested 
22q11.2 duplications as the first putative protective mutation for SCZ.
Duplications at 17q12 have been implicated in autism and mental retardation but their 
association with schizophrenia has not been previously reported. We observed more 17q12 
duplications in schizophrenia cases (5 cases and 1 controls, OR=6.27, 95% CI: 0.7–296.4, 
Pemp =0.07). In the replication data, 5 cases and 2 controls had 17q12 duplications 
(OR=4.16, 95% CI: 1.28-Inf, P=0.018 in a one-sided Fisher’s exact test; OR=4.05, 95% CI: 
1.35-Inf, P=0.024 in a one-sided Cochran-Mantel-Hänszel exact test). Table S13 and 
Figures S3–4 depict the 22q11.2 and 17q12 duplications from GWAS and exome arrays, 
confirming these events.
Szatkiewicz et al. Page 9






















We tested regions known to increase risk for developmental delay.36 Of 173 loci, 21 
deletions and 16 duplications overlapped (>20%) the Swedish schizophrenia results (Table 
2). Among the loci unique to developmental delay, no significant association with 
schizophrenia (empirical P > 0.05) was observed.
After excluding previously implicated loci (Table 2), 10,11,13,35,36 we identified 15 regions 
nominally associated with schizophrenia (empirical P < 0.01). Five regions had substantial 
overlap with segmental duplications (>50%) and were excluded. None of the remaining 10 
regions had strong evidence for association in the replication dataset (Table S14).
Gene set testing
Given that the rarest (single-occurrence) and the largest CNVs (>500 kb) had the strongest 
risks for schizophrenia, these subclasses were examined further. Gene set testing results 
obtained from single-occurrence CNVs did not reveal additional gene sets with significant 
enrichment (data not shown). Gene set testing results obtained from CNVs >500kb showed 
higher effect sizes compared to the corresponding tests based on CNVs >100Kb (Table 3, 
Table S16).
We hypothesized that different types of genetic variation can perturb the same biological 
pathways critical to the etiology of schizophrenia. To test this, we compared CNV rates in 
cases versus controls in gene sets previously implicated in schizophrenia (Table 3). The 
strongest enrichment was observed for CNVs (deletions and duplications combined) in 
neuronal calcium channel signaling (OR=2.48, 95% CI: 1.36–4.51, adj_Pemp =0.041 for 
events >100Kb; OR=4.39, 95% CI: 1.46–13.2, adj_Pemp =0.047 for events >500Kb). For 
CNVs >500Kb in SCZ cases, 56 events overlapped 11 genes of the calcium signaling 
pathway, among which 17 (30%) events overlapped (by >50%) known risk CNV loci (Table 
S17). A significant enrichment in FMRP targets44 (OR=1.7, 95% CI: 1.08–2.67, adj_Pemp 
=0.043) was observed for deletions >500Kb, of which 76 case deletions (36 in known loci) 
overlapped 28 genes (Table S17). Previously, the calcium channel and FMPR targets were 
enriched for rare exonic mutations in exome sequencing of half of the Swedish 
samples 7,14,47 and were enriched for common variants in a meta-analysis of the Swedish 
samples and independent PGC samples (a total of 13,833 cases with SCZ and 18,310 
controls). 7,14,47 We then examined the overlap between genes affected by common variants 
and by rare CNVs that are driving the enrichment signals in these two shared pathways. 
Table S15 shows that common variants affected more genes than rare CNVs did, and that 
common variants and rare CNVs had no overlap for calcium channel and a small overlap for 
FMRP targets. These results suggest that different types of risk alleles were independently 
enriched in SCZ cases than in controls.
For genes found at the post-synaptic density (PSD), we observed increased burden for the 
gene set used by Kirov et al.12 (OR=1.4, 95% CI: 1.12–1.74, adj_Pemp =0.067 for >500Kb 
deletions and duplications combined), and a stronger enrichment using the GO category 
“postsynaptic density” (OR=6.74, 95% CI: 1.66–27.3 for >500kb deletions, Table 4). We 
next tested gene sets comprising components of the PSD as in Kirov et al.12, and observed 
significant enrichment (adj_Pemp <0.05) in the NMDAR gene set and in genes encoding 
mGluR5 for >500Kb deletions and duplications combined, and in the PSD-95 (post-synaptic 
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density protein 95) complex for >500Kb deletions only (Table 3). Most of the case CNVs 
(~73%) overlapped three known risk CNV loci (3q29, 16p11.2, 22q11.2) and overlapped 
genes previously enriched for case de novo CNVs12 (Table S17). Overlap between de novo 
CNVs with 3q29 and 16p11.2 was previously reported.12
Gene products often localize to particular sub-cellular compartments. Identifying 
compartments enriched for genes impacted by CNVs in schizophrenia patients could provide 
greater insight into pathophysiological mechanisms related to the disorder. Besides the PSD 
genes, we tested additional gene sets enriched for de novo CNVs in Kirov et al.12 (Table 
S16) and observed significant enrichment for gene products localized to cytoplasm 
(OR=3.38, 95% CI: 1.49–7.68, adj_Pemp=0.012 for duplications >500Kb) and mitochondria 
(OR=4.31, 95% CI: 1.17–10.9, adj_Pemp=0.0049 for deletions >500Kb). Given the potential 
role of mitochondrial dysfunction in psychiatric disorders, 62,63 we further tested human 
nuclear-encoded mitochondrial genes in MitoCarta and found significant enrichment of case 
deletions (1.74, 95% CI: 1.12–2.71, adj_Pemp=0.022 for deletions >500Kb, Table 3). Half of 
the case CNVs (~51%) overlapped known CNV risk loci (Table S17).
Since many CNVs associated with schizophrenia also show pleiotropic effects for autism 
and mental retardation, we tested the genes implicated in these disorders in the Swedish 
sample (Table S16). Large CNVs (>500Kb duplications and deletions combined) in 
schizophrenia cases were enriched in genes implicated in mental retardation (OR=2.71, 95% 
CI:1.41–3.34, adj_Pemp = 0.0049). Approximately 33% case CNVs overlapped known CNV 
risk loci (Table S17), which is not surprising as many of the MR genes have been identified 
by genomic re-arrangements.
Schizophrenia is often associated with cognitive deficits. Therefore, we tested whether 
CNVs in schizophrenia patients were enriched for genes associated with cognitive ability in 
humans and neurological or behavioral phenotypes in mice (Table S16). We observed 
significant enrichment of large deletions (>500Kb) in synaptic genes based on functional 
group analysis48 (OR=1.67, 95% CI: 1.15–2.43, adj_Pemp=0.036). Although not significant 
based on multiple-testing adjustment, increased burden of deletions was observed in genes 
for which knockout in mouse yields a neurological or behavioral phenotype (OR=1.26, 95% 
CI: 1.06–1.49, Pemp=0.0021 for deletions >100Kb; OR=1.53, 95% CI: 1.11–2.1, 
Pemp=0.00099 for deletions>500kb).
The markedly increased sample size of this study relative to others provides the opportunity 
to identify novel biological pathways associated with schizophrenia. Therefore, we 
performed a series of exploratory analyses using gene sets based on KEGG, GO, and 
TargetScan (targets of microRNAs other than miR-137). Table 4 lists the top ranking gene 
sets that were significantly enriched in cases than in controls (all had p < 0.0002). For 
KEGG and TargetScan, all had q-value <0.01, implying that <1% of significant tests or 
<0.27 test will result in false discoveries; and for GO, all had q-value <0.004, implying that 
<0.4% of significant tests or <0.59 test will result in false discoveries. These gene sets 
included multiple elements of the immune system (T cell receptor signaling, hematopoietic 
cell lineage, positive regulation of monocyte proliferation), members of chromatin 
remodeling complexes (e.g. HDAC9, NCOR1), and a novel association with target genes of 
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microRNA miR-10a as well as basic elements of microRNA processing machinery 
necessary for gene silencing (i.e. DGCR8, ERI1, NCBP2). We investigated the potential role 
of miR-10a using the Swedish GWAS data.7 However, unlike miR-137, no significant 
GWAS hit was found in the vicinity of mirR-10a and the targets of miR-10a were not 
enriched for smaller GWAS P-values (data not shown).
Rare CNVs and significant GWAS loci
We asked whether CNVs were enriched in cases compared to controls in the genes 
implicated by GWAS meta-analysis of the Swedish samples and independent PGC samples 
(a total of 13,833 cases with SCZ and 18,310 controls).7 For 2,619 genes with GWAS P < 
10−3, we observed significant enrichment for large CNVs (OR=1.21, 95% CI: 1.1–1.33, 
adj_Pemp=0.0049 for >500kb deletions and duplications combined, Table 3).
Rare CNV and common variant burden
We computed the Spearman correlations between rare CNV burden and common variant 
burden (i.e., RPS), which were all near zero and not statistically significant (P > 0.05). Thus, 
the two types of genetic burden are uncorrelated. The relative impact of rare CNV burden 
and RPS burden was quantified by fitting multiple logistic regression models and estimating 
the effect size (R2). The two classes of variation were significantly, independently, and 
additively enriched in schizophrenia cases compared to controls (Table S18). Figure 4 and 
Tables S19 show the R2 values using CNV burden at known SCZ-associated loci 
(1q21.1del, 3q29del, 15q13.3del, 22q11.2del, 16p11.2dup, and all 5 loci combined). Figure 
S6 and Table S20 show the R2 values using burden of >100kb single-occurrence deletions, 
>500kb deletions, and CNVs in other categories. In summary, RPS accounted for at least an 
order of magnitude more variance than rare CNVs of strongest effects in this sample. 
Similar results were obtained using gene count and total length as CNV burden metrics (data 
not shown).
Exploratory analyses
We investigated the impact of deleterious mutations in BLM. Bloom syndrome is a rare 
Mendelian disorder characterized by genomic instability and excessive homologous 
recombination in affected individuals and is caused by recessive mutations in BLM. From 
exome sequencing in a subset of this sample (2,222 schizophrenia cases and 2,278 controls 
post-QC), there were 30 cases and 33 controls with a disruptive exonic mutation in BLM.14 
The presence of a BLM mutation was not associated with case-control status (P = 0.88 chi-
squared test), but individuals with BLM mutations had greater CNV burden compared to 
individuals without mutations in BLM (Table S21). For genic deletions, we observed a 
significantly (P = 0.0019) greater burden (as measured by the number of impacted genes) in 
individuals with deleterious BLM mutations (with the presence of a deleterious BLM 
mutation increasing CNV genic deletion burden by a mean of 0.96).
Discussion
This sample from Sweden provided an ideal CNV screening set since it is one of the largest 
schizophrenia samples yet collected in a single country and is relatively homogenous and 
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genomically well-characterized. Furthermore, we had the opportunity to validate CNVs 
using exome array data from the same samples as well as test for replication using large 
scale samples from the UK. 61
Consistent with previous reports, our results confirm increases in CNV burden in cases and 
recapitulate known specific CNV risk loci. We also identified an association of duplications 
at 17q12 with schizophrenia that is reciprocal of the known 17q12 deletion. We did not 
identify any novel CNV loci as enriched among schizophrenia cases. Our power analyses 
suggest that most rare and recurrent CNVs carrying moderate to high risk have been 
discovered with GWAS arrays (Figure 1). The CNV burden analyses imply that additional 
recurrent CNVs do exist; as these were among the rarest events, far larger sample sizes will 
be required for their confident identification.
Our primary analyses applied a stringent size filter (≥100kb and spanning ≥15 probes) 
because these events can be most reliably detected from GWAS arrays. 11,13 For secondary 
CNV analyses, we used more liberal thresholds (≥ 20 kb and spanning ≥10 probes) because 
of tradeoffs between sensitivity and specificity. However, we did not observe additional 
novel findings that exceeded genome-wide significance.
Gene set enrichment testing replicated a number of findings from the literature and 
identified novel biological processes potentially related to schizophrenia pathophysiology. 
Consistent with previous GWAS, exome sequencing, and CNV findings, we found 
enrichment for neuronal calcium channel signaling, FMRP binding partners, glutamate 
receptors (NMDA and mGluR5). The FMRP targets were also linked to synaptic function 
and autism.44 Novel pathways identified included: signaling components within the immune 
system not encoded by the MHC region previously associated with schizophrenia (T cell 
receptor signaling, hematopoietic cell lineage, positive regulation of monocyte 
proliferation), new microRNA pathway (miR-10a) along with basic microRNA processing 
elements (e.g. DGCR8, ERI1, and NCBP2), and members of chromatin remodeling 
complexes (e.g. HDAC9, NCOR1). These novel pathways underscore the importance of the 
immune system and microRNA-based regulation of gene expression for schizophrenia 
etiology and suggest that MHC and miR-137 may be just the first components of larger 
biological networks yet to be identified. Furthermore, the detection of multiple pathways 
involved in transcriptional regulation is consistent with the schizophrenia GWAS results, 
where the vast majority of associated loci are thought to tag regulatory variation.
On the phenotype level, we found that CNVs in schizophrenia patients are enriched for 
genes associated with mental retardation, cognitive ability in humans as well as neurological 
or behavioral phenotypes in knockout mice. These results are consistent with the pleiotropic 
effects of large, rare CNVs previously described in the human genetics literature. 
Furthermore, the mouse finding suggests that murine models provide a biologically relevant 
system to examine the pathological effects of gene dosage (via knockout or overexpression) 
on brain and behavior. On the subcellular compartment level, we identified enrichment for 
gene products localized to three regions: the post-synaptic density, mitochondria, and 
cytoplasm. The synaptic enrichments are consistent with pathways mentioned above 
(neuronal calcium, glutamate, and FMRP signaling) as well as a growing body of literature 
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implicating genes related to synaptic transmission in schizophrenia and bipolar 
disorder. 7,64,65
Mitochondria generate ATP by oxidative phosphorylation and play important roles in the 
regulation of cellular calcium levels, steroid synthesis, production of free radicals, and 
regulation of apoptosis. Brain is highly dependent on ATP generated by mitochondria. 
Mitochondrial dysfunction and a disturbance of energy metabolism have been observed in 
schizophrenia patients and, likewise, mitochondrial disorders can present with psychotic, 
affective, and cognitive symptoms. 62,63 Our data reveal that nuclear encoded genes that 
localize to the mitochondria are over-represented among large, rare CNVs in schizophrenia 
patients, lending credence to the mitochondrial dysfunction hypothesis.
By exome sequencing of over 5,000 of these subjects, Purcell et al.14 found that three 
classes of variation, as measure by rare CNV burden, common variant/RPS burden, and rare 
exonic variant burden, were uncorrelated and independently and additively enriched in SCZ 
cases compared to controls. Consistent with this report,14 we found that rare CNV burden 
and common variant/RPS burden are independently and additively enriched in SCZ cases. 
We note that it is currently unknown how environmental factors 5,6,66 interact with genetic 
burden. Consistent with Purcell et al.14, RPS burden accounted for at least an order of 
magnitude more variance than rare CNVs in this sample. This suggests that while the SCZ-
associated rare and large CNVs are much more penetrant individually than SCZ-associated 
common SNPs, they contribute much less to the overall population risk of schizophrenia 
than do the SNPs.
In the exome sequencing study, Purcell et al.14 found increased burden of rare exonic 
mutations in genes implicated by GWAS and in a known CNV risk locus 3q29/DLG1. Here 
we found increased burden of rare CNVs in genes implicated by GWAS. GWAS results are 
robust as they were based on a meta-analysis of the Swedish samples and a much larger 
independent PGC samples. The associated common variants were far more distributed both 
in more subjects and from more sequences in the genome than rare exonic variants or large 
rare CNVs. The burden of rare exonic variants, common variants, and rare CNVs were 
uncorrelated and independent. Together, these findings suggest that multiple lines of 
genomic inquiry – genome-wide screens for CNVs, common variation, and exonic variation 
– are converging on similar sets of pathways and/or genes. This convergence helps to 
increase confidence in the robustness of the findings and provides results relevant to 
resolving the rare “versus” common variation debate. Further work will be required to 
characterize the potentially mechanisms of these pathways.
We observed increased genic deletions in individuals with exonic BLM mutation, which is 
consistent with the fact that BLM mutations increase homologous recombination in the 
affected individuals. To identify genomic loci influencing individual differences in CNV 
burden, future investigation using large-scale trio data would be informative in order to 
assess how parental genotypes associated with meiotic CNVs in offspring.
We believe it is possible that CNV discovery for schizophrenia has entered a difficult phase 
where almost all low-hanging fruit have been collected (i.e., large, recurrent CNVs 
Szatkiewicz et al. Page 14






















measurable by SNP arrays). Increasing CNV discovery could well await dramatic 
improvements in sample size, technology, and cost. The detection of large, very rare 
recurrent CNVs will require marked increases in sample sizes. The application of whole 
genome sequencing to large case-control samples remains expensive but offers the 
possibility of confident identification of CNVs as small as 1 kb, particularly those that 
impact exons in single genes. 67 CNV technologies based on genotyping arrays do not 
perform well for copy number polymorphisms (frequency > 0.01), 68 and is it certainly 
possible that this class of variation has explanatory power in schizophrenia but is currently 
not well measured.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Power to detect novel and known risk loci. The three solid lines depict the minimal 
detectable genotypic relative risk (y-axis) as a function of the risk allele frequency in the 
population (x-axis) to achieve 20%, 25%, 80%, 90%, and 95% power. Assumptions were 
4,719 cases/5,917 controls, a dominant model, lifetime risk of schizophrenia of 0.7%, and α 
= 0.05. An additive model produced nearly identical results. Nine known CNVs associated 
with schizophrenia are shown as red diamonds (P < 0.05 in this study) or black dots (not 
detected). For each risk locus, the estimated OR and allele frequency in controls were 
obtained from the literature. If not found in controls, allele frequencies were set to 0.0001. 
The four most replicated loci (22q11.2−, 15q13.3−, 1q21.1, and 16p11.2+) can be detected 
given our sample size. Loci 17q12−, 3q29−, 1q21.1+, and VIPR2+ likely have imprecise 
estimates of GRR or frequency as evidenced in large discrepancies between various reports.
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Experimental workflow and CNV datasets.
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Genome-wide CNV burden. These forest plots show OR estimates and 95% confidence 
intervals for each burden test. The size of the square is proportional to precision. Allele 
frequency categories: 1x means single-occurrence CNVs observed once in a case or control 
(MAF < 0.0001). These were conservatively defined as having no overlap with any other 
CNVs. 2–6x means 2 to 6 occurrences (MAF 0.0001–0.0005). 7x+ means ≥7 occurrences 
(MAF 0.0005–0.01).
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Relative impact of rare CNV burden and common variant allelic burden. We computed the 
difference in the Nagelkerke pseudo R2 score to estimate the proportion of variance of case-
control status in the Swedish samples accounted for by the common variant allelic burden 
(risk profile scores, RPS) and by the rare CNV burden (as measured by the number of CNV 
at known SCZ-associated loci). We examined CNV burden of 1q21.1del, 3q29del, 
15p13.3del, 22q11.2del, 16p11.2dup, individually and combined. The Y-axis of the barplot 
shows the estimates of effect size (i.e. Nagelkerke pseudo R2). RPS accounted for at least an 
order of magnitude more variance than rare CNVs in this sample.
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Table 1
Subject and CNV characteristics.
Sample characteristics Cases Controls
Subjects (after quality control)
 Sw1 (Affymetrix 5.0) 207 206
 Sw2–4 (Affymetrix 6.0) 1,847 2,137
 Sw5–6 (Illumina Omni Express) 2,665 3,574
 Total sample 4,719 5,917
Male sex 0.599 0.513
Median age at sampling 54 (45–62) 57 (48–65)
Median hospital admissions for schizophrenia 6 (3–13) n/a
Median total inpatient days 239 (79–694) n/a
Median years from first to last admission 9.7 (2.9–19.5) n/a
Proportion of all CNVs that are deletions
 Sw1 0.40 0.47
 Sw2–4 0.37 0.36
 Sw5–6 0.40 0.40
 Total sample 0.38 0.38
Median CNV size
 Sw1 181.3 178.0
 Sw2–4 182.2 188.2
 Sw5–6 183.1 190.7
 Total sample 182.7 188.8
Mean number of CNVs per subject
 Sw1 1.058 0.845
 Sw2–4 1.236 1.209
 Sw5–6 0.758 0.684
 Total sample 0.958 0.879
After quality control, the combined sample size is 10,636, where Sw1=413 (3.9%, Affymetrix 5.0), Sw2–4=3,984 (37.5%, Affymetrix 6.0), and 
Sw5–6=6,239 (58.7%, Illumina OmniExpress). Values in parentheses are inter-quartile ranges. Cases had significantly more males (p < 0.0001) 
and were significantly younger (p < 0.0001) than controls although these differences were not of large magnitude. The higher median age in 
controls is in the direction of greater confidence in control classification (i.e., controls had greater time at risk for psychiatric hospitalization). The 
mean number of >500Kb CNVs and of singleton CNVs are reported in Table S8.
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